Aibotics, Inc NT 10-Q, filed May 19, 2021
Aibotics, Inc. (AIBT)
| UNITED STATES |
| SECURITIES AND EXCHANGE COMMISSION |
|
|
| Washington, D.C. 20549 |
|
|
| FORM 12b-25 |
|
|
|
|
| NOTIFICATION OF LATE FILING |
|
|
|
|
(Check One): | o Form 10-K | o Form 20-F | o Form 11-K | x Form 10-Q | o Form 10-D | o Form N-CEN | o Form N-CSR |
For Period Ended: March 31, 2021
o Transition Report on Form 10-K
o Transition Report on Form 20-F
o Transition Report on Form 11-K
o Transition Report on Form 10-Q
For the Transition Period Ended: _____________________________________________________________
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
|
PART I -- REGISTRANT INFORMATION
Mycotopia Therapies, Inc. |
Full Name of Registrant
20/20 Global Inc. |
Former Name if Applicable
18851 NE 29th Ave., Suite 700 |
Address of Principal Executive Office (Street and Number)
Aventura, FL 33180 |
City, State and Zip Code
PART II -- RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
| (a) | The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
x | (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
| (c) | The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
1
PART III -- NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed.)
We were unable to file our quarterly report on Form 10-Q for the quarter ended June 30, 2019, within the prescribed period because we were unable to timely complete and verify our financial statements.
PART IV -- OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this notification
Jonathan Leinwand |
| 954 |
| 903-7856 |
(Name) |
| (Area Code) |
| (Telephone Number) |
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
| x Yes | ¨ No |
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
| Yes x | ¨ No |
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
In January 2021 there was a change of control of the business and the implementation of a new business plan. It is expected that the Company will sustain a loss of $8,240 from operations for the period.
Mycotopia Therapies Inc. |
(Name of Registrant as Specified in Charter) |
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date: | May 17, 2021 | By | /s/ Ben Kaplan |
|
|
| Ben Kaplan, President |
|
|
| Chief Executive Officer (Principal Executive Officer |
|
|
| and Principal Financial Officer) |
2